An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib

ovartis0 个研究点目标入组 5 人开始时间: 2015年12月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patient is currently receiving treatment with ceritinib within a Novartissponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment.
•-Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
•-Wilingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
•-Written informed consent obtained prior to enrolling in the roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.

•-Patient has been permanently discontinued from ceritinib study treatment in the parent study due to any reason.
•-Patient currently has unresolved toxicities for which ceritinib dosing has been interrupted in the parent study. (Patients meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow ceritinib dosing to resume.)
•-Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test.
•-Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception.

发起方